Background: There is on ongoing debate in the literature regarding the real burden of STIs (sexually transmitted infections) in Western countries and the proper strategies needed to estimate and to prevent them. Our purpose is to present an evidence-based national strategic plan for STI prevention in Israel through assessing the current burden of illness, leading international preventive strategies, and practical policymaking experience. Methods: Epidemiologic and health policy data on STIs were analyzed from various sources: a) systematic national surveillance data for the years 2002-2014; b) the international scientific literature (published between 2002-16; keywords: Sexually Transmitted Diseases (STD) (or STI) AND prevention AND intervention AND gonorrhea OR chlamydia OR syphilis; c) internal Ministry of Health (MOH) analyses and reports, and d) expert opinion.
Introduction
The incidence rates of the three main sexually transmitted infections (STIs) (other than HIV) in Israel-Chlamydia trachomatis (chlamydia), Neisseria gonorrhea (gonorrhea), and Treponema pallidum (syphilis) are lower than those in most western countries [1, 2] . However, these rates may actually be higher due to under-reporting of new cases. Additionally, if appropriate preventive and therapeutic measures are not implemented in a timely fashion, rates may rise due to the following factors: (1) importation of additional cases by migrants from countries with either high prevalence levels of STIs or from countries experiencing recent epidemic outbreaks followed by dissemination within the veteran population; (2) international travel by a native and migrant residents; (3) a significant prevalence of commercial sex work (CSW) in urban areas [2] .
Meeting these challenges requires a thorough mapping of the STI epidemiology in Israel, the development of a comprehensive preventive strategy, as well as a practicable implementation program. These challenges have been addressed within the context of a national prevention initiative entitled 'Healthy Israel 2020' , which aims to increase the life expectancy and the quality of life of Israel's citizens, while reducing health inequity (specific recommendations for STIs have been postponed to 2025). Topic areas for the entire initiative were selected on the basis of their respective burdens of disease [3] . One of the topic areas covered the prevention of infectious diseases; a subcommittee thereof focused on the prevention of Tuberculosis (TB), HIV, and STIs. Recommendations on the topics of TB-HIV have been published elsewhere [4] . The current integrative article focuses on the development of national targets and objectives for the reduction of the disease burden due to STIs by the year 2025, as well as an evidence-based, and implementable strategic plan to achieve that aim.
Methods
Data on the epidemiology, preventive interventions and best practice implementation strategies for the prevention of the three main STIs in Israel were analyzed and accessed from various sources. Systematic surveillance data collected by the Division of Epidemiology in the Israeli Ministry of Health (MoH) for the years 2002-2014 was used to describe epidemiological STI data on the Israeli population in addition to internal MOH analyses and reports ("grey literature"). Country-level STI incidence rates were collected from the databases of the World Health Organization (WHO) Regional Office for Europe, the US CDC, and the Australian National Notifiable Disease Surveillance System. Primary and secondary preventive interventions to reduce the burden of STIs published between 2002 and 2016 were accessed from the English language scientific literature by entering the following keywords into PubMed: Sexually Transmitted Diseases (STD) (or STI) AND prevention AND intervention AND gonorrhea OR chlamydia OR syphilis. Twenty one articles describing preventive interventions were retrieved, primarily from European countries and the United States (US) for each specified STI (gonorrhea, chlamydia or syphilis). Particular attention was focused on data/recommendations issued by evidence-based international and other national preventive health oriented organizations such as, the WHO, the Cochrane collaboration, the US Preventive Services Task Force, the Task Force for Community Preventive Services, as well as various European countries.
Throughout our investigation, numerous discussions were held between the MoH staff, several stakeholders (both governmental and non-governmental), and senior medical professionals; these were further elaborated upon by the Healthy Israel 2020 sub-committee on STIs in order to develop a coherent, evidence-based national plan to reduce the burden of STIs in Israel.
Results

Epidemiology International
Incidence rates for the three main STIs vary widely between countries and show different trends over time. When analyzing the 53 WHO European countries, many did not report STI incidences annually to the WHO European region [1] . Incidence trends (per 100,000 population) from countries who regularly reported to WHO European region, including Israel, were accessed for the years 2006-2013 [1] . In addition, trends in the US and Australia were also analyzed for this period [5, 6] .
Chlamydia Incidence rates (per 100,000 population) in the 27 WHO European region countries which reported data for the year 2012 were highest in the Scandinavian countries; Iceland led this region with 576 cases/ 100,000. Rates tended to decrease merely from north to south: the United Kingdom -378, Belgium -43, Israel -10.8, and Spain a mere 1.9. The high rates of Chlamydia and discrepancies between Scandinavian countries and other countries are also a partial reflection of ascertainment and reporting biases.
Most of the WHO European region European countries reviewed showed a distinct increase over the years 2006-2013. This increase was noted in other countries as well: the rate in the USA increased from 344/100,000 in 2006 to 443/100,000 in 2013 [5] ; and in Australia, increased from 230/100,000 in 2006 to 363/100,000 in 2013 [6] .
Gonorrhea Incidence rates (per 100,000 population) in the 34 WHO European region countries which reported data for the year 2012 were much lower than those of chlamydia, ranging from 45.5 in the United Kingdom and 36.5 in the Russian Federation, to 0.45 in Italy, 0.16 in Montenegro and 0.11 in Bosnia [1] . Many countries experienced fluctuations during the years 2006-2013. Israel's rates fluctuated between 2.1 and 4.1/100,000 during this period. US rates decreased from 2006 to 2009, but then began to rise again. US rates were significantly higher than those in the European region, reaching 105.3/100,000 in 2013 [5] . Australia has also experienced fluctuating rates, with 41.6/100,000 in 2006, 35.7/100,000 in 2008, but rising to 64.5/100,000 in 2013 [6] .
Primary and secondary early syphilis Incidence rates (per 100,000 population) in the 25 WHO European region countries which reported data for the year 2012 were all of the same order of magnitude, ranging from 11.9 in Georgia to 1.3 in Sweden [1] (except the Republic of Moldova which reported an exceptionally high rate of 64.7). Israel, though, reported an even lower rate: 0.9/ 100,000. Since 2006, slightly more countries have noted an increase rather than a decrease in incidence trends, but in most they fluctuated. The US rate of 5.5/100,000 in 2013 is higher than that seen in almost all European countries [5] . Australia has experienced fluctuating rates, with 4.3 in 2006 rising to 6.8 in 2007, dropping to 5.1 in 2010, but then rising again to 7.6 in 2013 [6] .
On the basis of current passive surveillance, incidence rates of chlamydia, gonorrhea and syphilis are low in Israel relative to northern European countries [1] , the USA [5] and Australia [6] , and are roughly similar to those reported by southern Mediterranean European countries.
Israel: an in-depth analysis
In 1994, Chlamydia was added to the list of STIs already defined in Israel as reportable diseases. STI incidence rates by population groups (for the period 2002-2014) appear in Figs. 1, 2 and 3.
The main findings were as follows:
Rates of chlamydia are appreciably higher in Jews than in non-Jews. This difference has increased over the past decade. Overall, rates have markedly increased in recent years (from 2.9/100,000 in 2006 to 11.3/100,000 in 2014). Rates of gonorrhea have decreased in the last decade, and are approximately three times higher in Jews than in non-Jews. Males account for the majority of the cases (male to female ratio >4). Increasing requests for bacteriologic testing of pharyngeal specimens, especially in men having sex with men (MSM) and in CSW, may indicate an increasing trend in the transmission of pharyngeal gonorrhea [7] . The rates of syphilis are roughly three to four times higher in Jews than in non-Jews. Between the years 2002-2011, rates have dropped by over 70% in the Jewish population and by 80% in the non-Jewish population, before increasing back since 2012 and forming a U-curve, especially prominent among the Jewish population. This recent increase is largely influenced by an increase of reported new male cases, which are assumed to be mostly among MSM, the group at the greatest risk of infection in recent years [8] . The number of cases of syphilis among HIV-infected MSM increased from 0 to 2 cases/year in the 1990-2000 period to 10-18 cases/year during the 2005-2009 period. In the Tel Aviv district, where 90% of the patients were MSM, the number of males infected with syphilis increased from 5 cases in 2005 to 40 cases in 2009. In the MoH STI clinic in Tel-Aviv, 1,064 (22%) MSM and 3,755 (78%) heterosexuals were tested. Positivity rates for HIV, urethral N. gonorrhea and infectious syphilis in MSM were higher than in heterosexuals (2.5%, 2.5%. 0.7% vs. 1.6%, 1.3%, 0.3%, respectively), while urethral C. trachomatis was higher in heterosexuals than in MSM (2.7 vs. 1.4%, respectively) [9] . At National level, the peak age of incidence of all three STIs was 15-44, where the 25-34 year old age group suffered the greatest burden of infection. Further analysis of incidence trends in these three major STIs by age group (15-24; 25-34; 35-44) appears in a recent publication [2] .
Setting the 2025 objectives and targets
The aforementioned data sources resulted in the generation of the following baseline incidence rates for the three STIs of interest in 2014:
Chlamydia: 11.3/100,000 Gonorrhea: 3.2/100,000 Primary and secondary syphilis: 2.3/100,000
The current Israeli STI surveillance system is predominantly passive and therefore the generated data is inherently incomplete due to partial reporting and capture of disease incidence data. Conversely, when setting target goals and national objectives to decrease the rates and/or the burden of disease, it is critical to establish more authoritative baseline values. These limitations led to the decision by the authors of this article to defer the definition of the 2025 objectives and target values until more accurate baseline values could be generated. [13] [14] [15] [16] [17] [18] [19] year olds to be counseled in matters regarding sexual behavior, STIs and contraceptive use. This is optional for 20-39 year-olds. No information is provided about the manner (methodology, training, frequency, duration etc.) in which this counseling is to be performed [15] .
Interventions
Primary prevention
Secondary prevention (screening)
A. Evidence of efficacy 1. Chlamydia Two randomized controlled trials demonstrated a reduction in medical complications in women members of a Health Maintenance Organization (HMO) and in a high school that implemented Chlamydia screening [16, 17] . A recent summary article from the US CDC justified screening sexually active young, as well as high risk older females, due to the large and costly burden of preventable illness (presenting as pelvic inflammatory disease (PID) and its sequela, tubal infertility), the asymptomatic nature of the infection in females, the ease of diagnosis with nucleic acid amplification tests, the highly efficacious treatment options, and the randomized trial data showing a reduction in PID incidence following screening [18] . Conversely, a systematic review did not find evidence for even opportunistic screening of women younger than age 25, if not considered as high risk [19] . A Cochrane review found Chlamydia screening to have only a modest effect in reducing PID risks at the individual level, but had no effect on epididymitis or on infection levels among in men and women [20] .
Gonorrhea
Indirect evidence shows that screening sexually active women age 24 and younger, as well as older women at increased risk of infection (those with a new or more than one sexual partner, a sexual partner infected with an STI, inconsistent condom use, a history of previous or coexisting STIs, or those exchanging sex for money of drugs) may prevent other complications associated with gonococcal infection, such as pelvic inflammatory disease and its sequelae [21] .
Syphilis
Screening tests for syphilis can adequately diagnose the disease. Effective and cheap antibiotic treatment is also available for cure. High risk individuals (including MSM, CSW, and adults in correctional facilities) have a higher pre-test probability of being diagnosed with syphilis. Despite the above, there are insufficient data to conclusively prove that screening reduces syphilis-related morbidity [22] . The recommendation to screen pregnant women is based upon observational evidence that screening decreases the proportion of newborns with clinical manifestations of syphilis infection and those with positive serology [23] .
B. Cost-Effectiveness
In a review of 55 cost-effectiveness studies focused primarily on Chlamydia and HIV interventions, one-on-one interventions such as counseling (and screening) were proven to be cost-effective [24] . An editorial on the article [25] noted that these cost-effectiveness calculations were conservative because the benefits of STI prevention such as reduction of HIV incidence and productivity losses were excluded. A cost-utility analysis of Chlamydia screening calculated that the incremental costeffectiveness ratio relative to the next most effective strategy would cost less than $25,000 USD/QALY for annual screening followed by semi-annual screening for those with a history of infection, thus classifying it as very cost effective [26] . This has been corroborated by a more recent United Kingdom (UK) calculation based on modeling: it was estimated that it would cost £506 (=US $776 -Conversion rate as of April 15, 2013) per infection treated [27] . Israeli cost-effectiveness data is not yet available.
C. Screening policies in selected western countries US Chlamydia and Gonorrhea
The USPSTF recommends that all sexually active women aged 24 and younger, as well as for older women at high risk for STI be screening for chlamydia and gonorrhea. High risk is defined as those with one of the following risk factors: those with a history of previous or concurrent STI, those with a new or more than one sexual partner, a sex partner who is currently infected with STI, sporadic (inconsistent) use of condoms, and those who exchange sex for drugs or money. Grade: B recommendation [21] . Syphilis The USPSTF strongly recommends that persons at increased risk for syphilis infection be screened by clinicians. These include MSM engaged in high-risk sexual behavior, CSW, persons who exchange sex for drugs, and those in adult correctional facilities. Grade: A Recommendation [28] . The USPSTF strongly recommends all pregnant women be screened for syphilis infection.
Grade: A Recommendation [29]. EU (European Union)
Chlamydia In guidance presented in June 2009, The European Centre for Disease Prevention and Control (ECDC) recommended a step-by-step chlamydia control strategy whereby primary prevention, case management, and opportunistic testing to specified sub-populations attending clinical services be carried out, and evaluated, alongside the development of both patient management infrastructures, and quality controls before population-based screening be enacted [30] .
Most European countries lack a national screening program for Chlamydia for asymptomatic individuals [30] . A national Chlamydia screening program was put into place in the UK in 2007 [31] for women under age 25 attending various clinical and non-clinical settings (e.g., universities and sporting events). A pilot program of annual postal invitation was introduced in three regions of the Netherlands in [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] year-olds in early 2008 [30] . A registerbased screening program using mailed homecollected specimens is planned in Norway [30] . Opportunistic screening is widespread in Sweden but it lacks national coordination and is conducted on a county basis. Several northern European countries perform opportunistic testing of asymptomatic individuals, e.g., Denmark tests people with frequent sex partner change and women aged 25 and under before an IUD insertion (although in two of sixteen communities in the country proactive screening has been introduced -via postal invitation) [30] . Iceland screens all women presenting for termination of pregnancy and egg or sperm donors [30] . Canada recommends populationwide screening [32] . Since 2005, Australia has been moving in this direction [33] . Gonorrhea UK (United Kingdom) [34] There is no basis to support widespread, unselected screening for gonorrhea where only meager evidence for selective community screening exists in the UK. STI data is limited for those treated outside the genitourinary medical (GUM) clinics and prevalence studies are rare. The prevalence of gonorrhea infection varies widely between and within communities and patient populations. Gonorrhea diagnoses and subsequent complications are infrequent compared to chlamydia. Higher prevalence of infection than the general population is found among inner-city residents, STIs clinics attendees, military personnel, prisoners and MSM. The immediate health benefits from an accurate gonorrhea diagnosis are the subsequent reduction of HIV transmission or acquisition risk, support such an intervention. However, the health benefits must be weighed in light of the cost and adverse effects of screening. Localized interventions targeted at the core high-risk groups are likely to be more costeffective and beneficial than unselected community-wide screening. Rationale: these recommendations dovetail with USPSTF recommendations [28, 29] except with regard to adults in correctional facilities. According to Israeli correctional facility health reports (Aurkin-Tischler D, Israeli Prison Services. Personal communication, 2012), screening is not required because syphilis does not pose a serious threat to this population.
Discussion
Conservative MoH policy regarding STI screening in Israel reflects the relatively low national incidence of STIs, although underestimation is almost certainly an important issue, similar to many countries [36, 37] . Underestimation results from passive surveillance systems' inability to capture true population STI incidence, most likely originating from structural and functional limitations, and threatens accurate reporting due to the intrinsic biases of these systems. Therefore we recommend implementing measures to optimize the existing passive surveillance system including supplementing it with a robust, active surveillance system (as has already been accomplished for HIV in Israel [38] 
Conclusions
A national STI (chlamydia, gonorrhea, and syphilis) prevention strategy for the year 2025 is presented.
Although the current burden of STIs is relatively low compared to other Western countries, this is thought to be a partial result of underreporting. These and other gaps suggest a need for focused epidemiologic and health services research utilizing strategies such as active surveillance and field surveys to better characterize health risk behaviors as well as provider practice patterns. Primary preventive counseling is recommended for adolescents and younger adults. Due to the low prevalence of chlamydia and gonorrhea, only case finding in high risk populations is recommended. Screening with the VDRL test or the ELISA test is suggested for pregnant women, MSM, those exchanging sex for drugs, and CSW. Innovative implementation strategies include: cross-training of existing MoH TB personnel, enhanced training and interface with community clinical specialists, and procurement of more advanced diagnostic and analytic tools at all levels of care, in conjunction with expanded authorization of healthcare personnel to avail themselves of these tools. Implementation of these recommendations will require a commitment to reasonably increase the capacity of the Department of TB and AIDS and satellite organizations including increased staffing, development of specific training modules for infectious disease and primary care professionals, and major improvements of the existing technical infrastructure, including improvement in efficient and overall quality of laboratory diagnostic capabilities.
This should provide a strong foundation upon which to develop specific and implementable national STI prevention policy recommendations by 2025. 
